

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY AGREEMENT
CONVEYING PARTY DATA	
Name	Execution Date
Concordia Pharmaceuticals Inc.	05/06/2013
RECEIVING PARTY DATA	
Name:	Fulcrum Capital Partners Inc.
Street Address:	79 Wellington Street West
Internal Address:	Suite 3510
City:	Toronto, Ontario
State/Country:	CANADA
Postal Code:	M5K 1K7
PROPERTY NUMBERS Total: 4	
Property Type	Number
Patent Number:	5484607
Patent Number:	6030642
Patent Number:	5869100
Patent Number:	5763449
CORRESPONDENCE DATA	
Fax Number:	7168194678
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	7168564000
Email:	gsnyder@hodgsonruss.com
Correspondent Name:	Hodgson Russ LLP
Address Line 1:	140 Pearl Street, Suite 100
Address Line 2:	The Guaranty Building
Address Line 4:	Buffalo, NEW YORK 14202-4040
ATTORNEY DOCKET NUMBER:	030008.00020
NAME OF SUBMITTER:	George L. Snyder, Jr.

CH \$160.00 5484607

PATENT

Signature:	/george l snyder jr/
Date:	05/14/2013
Total Attachments: 3 source=Fulcrum-Collateral_Assignment_Patents#page1.tif source=Fulcrum-Collateral_Assignment_Patents#page2.tif source=Fulcrum-Collateral_Assignment_Patents#page3.tif	

COLLATERAL ASSIGNMENT FOR SECURITY

Patents

WHEREAS, **CONCORDIA PHARMACEUTICALS INC.**, incorporated in Barbados with company number 36557 and having its registered office at Chancery House, High Street, Bridgetown, Barbados (herein referred to as "**Assignor**"), has filed for or has been granted the patent applications and the patents listed on the annexed Schedule 1, which patent applications and patents are registered in, or are the subject of pending applications for registration in, the United States Patent and Trademark Office (the "**Patents**");

WHEREAS, Assignor and Fulcrum Capital Partners Inc. (the "**Assignee**") are parties to that certain Intellectual Property Security Agreement (the "**IP Security Agreement**") to secure the payment of the Secured Obligations (as defined in the IP Security Agreement);

WHEREAS, pursuant to the IP Security Agreement, Assignor has granted to Assignee a security interest in all right, title and interest of Assignor in and to the Patents, together with the goodwill of the business symbolized thereby and the applications and registrations thereof, and all proceeds thereof, including, without limitation, any and all causes of action which may exist by reason of infringement thereof (as further described in the IP Security Agreement, the "**Collateral**"), to secure the prompt payment and performance of the Secured Obligations;

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, Assignor does hereby grant to Assignee a security interest in the Collateral to secure the prompt payment and performance of the Secured Obligations.

Assignor does hereby further acknowledge and affirm that the rights and remedies of Assignee with respect to the security interest in the Collateral made and granted hereby are more fully set forth in the IP Security Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein.

Assignee's address is:

79 Wellington Street West, Suite 3510
Toronto, ON M5K 1K7


IN WITNESS WHEREOF, Assignor has caused this Collateral Assignment for Security to be duly executed by its officer thereunto duly authorized as of the 6th day of May, 2013.

CONCORDIA PHARMACEUTICALS INC.


By:

Name:

Title:


JOHN A.R. MCLEERY
MANAGING DIRECTOR

Before Me:


Notary Public
WITNESS

Address: Chancery House, High Street, Bridgetown, Barbados

[Signature Page - Collateral Assignment for Security - Patents]

SCHEDULE 1 TO COLLATERAL ASSIGNMENT FOR SECURITY

Patents

<u>Title</u>	<u>Country</u>	<u>Appl. No.</u>	<u>Filing Date</u>
<u>Patent No.</u>	<u>Date of Grant</u>		
1. <u>Extended release clonidine formulation</u>	US	08/136,309	10/13/93
5,484,607	1/16/97		
2. <u>Extended release clonidine formulation (capsule)</u>	US	08/884,283	6/27/97
6,030,642	2/29/00		
3. <u>Extended release clonidine formulation (tablet)</u>	US	08/881,314	6/24/97
5,869,100	2/9/99		
4. <u>Pleasant-tasting aqueous liquid composition</u>			
<u>Of a bitter-tasting drug</u>	US	08/692,081	8/7/96
5,763,449	6/9/98		